A generation of transformative therapies is arriving for Duchenne muscular dystrophy. Gene therapies have reached the clinic. Oral small molecules targeting the fundamental biology of the disease are entering clinical trials. Newborn screening programmes are being adopted across multiple countries. And new science is fundamentally rewriting our understanding of when Duchenne actually begins in the body. Yet for many patients, muscular dystrophy diagnosis still comes years too late to access them.
Yet for most children born with DMD today, the average age of diagnosis remains somewhere between four and five years old. In limb-girdle muscular dystrophy, some patients wait up to eight years from first symptoms to confirmed genetic diagnosis. In Europe, a study of adult patients in Berlin found a mean time of 4.3 years from first healthcare contact to diagnosis, with longer delays for patients initially seen by non-neurological specialists and for women.
This is the central paradox of muscular dystrophy in 2025: science is accelerating. Systems are not keeping pace.
A Condition Hiding in Plain Sight
Muscular dystrophies are a group of more than 50 inherited genetic disorders characterised by progressive muscle degeneration and weakness. DMD is the most common childhood-onset form, affecting approximately 1 in 3,500 to 5,000 live male births globally. Several forms, including DMD, are X-linked and affect males almost exclusively, while others such as myotonic dystrophy and LGMD affect males and females equally. The broader family spans a wide clinical and genetic spectrum, including facioscapulohumeral muscular dystrophy (FSHD), myotonic dystrophy type 1, and the limb-girdle muscular dystrophies (LGMDs), each presenting distinct diagnostic challenges.
Neuromuscular diseases collectively affect around 500,000 EU citizens and result in significant costs for families and healthcare systems. A 2020 systematic review published in the Orphanet Journal of Rare Diseases estimated the pooled global DMD prevalence at 7.1 cases per 100,000 males, with a birth prevalence of 19.8 per 100,000 live male births.
Despite well-documented clinical presentations, diagnosis comes late, and it comes late consistently across geographies, health systems, and resource levels.
The Diagnosis Delay Is a Global Problem
The tendency to frame diagnostic delay as a failure of under-resourced systems does not hold up. Muscular dystrophy diagnosis rates have not improved in line with scientific progress, and the gap is measurable across every major healthcare system. For boys with DMD, diagnostic delays have remained unchanged over the past three decades, with late diagnosis persistently noted in ethnic minority groups.
In the United States, data show an average delay of 2.5 years between symptom onset and confirmed diagnosis. A 2025 study found that parents typically raise concerns around 29.8 months of age, citing motor delays, walking difficulties, and speech problems, yet children frequently pass through multiple consultations before reaching a specialist.
In Germany, a study at the Charité in Berlin found a mean diagnostic delay of 4.3 years across muscle dystrophies, with longer delays when patients were initially seen by non-neurological specialists, and independent associations between diagnostic delay and female gender. Female DMD carriers can themselves be symptomatic and frequently go unrecognised.
In Canada, a 2025 study in Health Expectations documented five recurring themes among LGMD patients: difficulty navigating the diagnostic process; barriers to genetic testing and specialist access; disconnect from healthcare professionals; emotional distress; and significant impact on mobility. The average time from symptom onset to confirmed diagnosis was eight years.
EURO-NMD, the European Reference Network for Rare Neuromuscular Diseases, brings together 61 leading centres across 14 EU member states and sees more than 100,000 NMD patients annually. The network has set a target of reducing time to diagnosis by 40 per cent in its first five years.
In Australia, a 2024 multi-centre study in The Lancet Regional Health: Western Pacific found that late diagnosis results in missed opportunities for clinical trial participation and access to newly approved therapies, particularly for children from ethnic minority backgrounds.
Primary Care Is the Weak Link, Everywhere
The common factor across geographies is not a lack of available diagnostic tools. It is inconsistent engagement with those tools at the point of first contact. Improved education for primary care clinicians is urgently needed to enhance recognition of neuromuscular disorders and facilitate earlier access to therapies.
A EURO-NMD survey found that while 94 per cent of specialist centres use next-generation sequencing, the diagnostic process can still take months or years for patients navigating the system. The Muscle Working Group has published diagnostic flowcharts for myotonic dystrophies and rhabdomyolysis and committed to further flowcharts in 2025 covering FSHD, Pompe disease, and myositis, alongside a series of 10 clinician education webinars.
Closing the gap requires sustained investment in education, referral pathway redesign, and the integration of genetic literacy into general clinical training.
The Biology Is Being Rewritten
Research from the Ottawa Hospital Research Institute, published in November 2025 in Nature Communications, challenged the established view that individuals with DMD are born with normal muscles that deteriorate over time. The study found that DMD is characterised by abnormalities in muscle stem cells during foetal development, suggesting the disease may begin in the womb, with affected individuals potentially born with pre-existing muscle deficits.
“These findings make it abundantly clear that Duchenne begins as a failure of muscle stem cells to build and maintain muscle, without any evidence of muscle fibre fragility or damage,” said Michael Rudnicki, PhD, co-author of the study.
If confirmed, the therapeutic window for meaningful intervention may be earlier than previously thought, with important implications for screening design and clinical trial endpoints.
A comprehensive review in Biomedicines in July 2025 reinforced the complexity of achieving accurate prognosis even after diagnosis. Research identified 13 previously unreported dystrophin gene variants and concluded that a combined approach using clinical evaluation, molecular analysis, and histological examination is essential. Cardiac complications remain underappreciated: one study found the fragmented QRS complex, a marker associated with myocardial fibrosis, in 91 per cent of DMD patients studied.
A Therapeutic Pipeline That Depends on Early Diagnosis
The pace of therapeutic development in DMD has accelerated sharply, making the persistence of late diagnosis an increasingly costly failure. Timely muscular dystrophy diagnosis has never been more consequential.
In 2023, Sarepta Therapeutics’ Elevidys became the world’s first FDA-approved gene therapy for DMD. Its performance remains contested: the primary endpoint was not met in the Phase 3 EMBARK trial. In June 2025, the FDA issued a safety communication following reports of fatal acute liver failure in at least two non-ambulatory paediatric patients treated with Elevidys. By November 2025, the FDA had approved a boxed warning and restricted the indication to ambulatory patients aged four and older, removing access for non-ambulatory patients entirely.
Elevidys is priced at $3.2 million, and products with uncertain risk-benefit profiles risk straining rare disease budgets. In July 2025, the EMA’s CHMP issued a negative opinion on Elevidys, declining to recommend it for conditional marketing authorisation in the EU. This regulatory divergence raises important questions about evidence standards and access equity across jurisdictions.
Multiple companies are advancing antisense oligonucleotide therapies targeting specific exon mutations. An FDA-authorised Managed Access Programme was initiated for Avidity Biosciences’ del-zota in November 2025. Japanese pharmaceutical company Nippon Shinyaku is advancing next-generation ASO approaches through NS Pharma, reflecting the international character of this pipeline.
SAT-3247, developed by Canadian biotech Satellos Bioscience, targets AAK1, a protein identified as capable of replacing the dystrophin signal in muscle stem cells to support muscle restoration. The approach is mutation-agnostic, a meaningful advantage given the genetic heterogeneity of DMD. In December 2025, Satellos received FDA clearance and global regulatory approvals to initiate a Phase 2 study in ambulatory children.
The point is direct: current and pipeline therapies require functional muscle to work with. Every year of diagnostic delay is a year of irreversible muscle loss that no therapy can restore.
Newborn Screening: A Global Picture Still Being Written
In December 2025, the US formally approved the addition of DMD to the Recommended Uniform Screening Panel. Minnesota had already moved ahead in February 2025, using creatine kinase measurement in dried blood spot specimens followed by molecular analysis to confirm dystrophin gene variants.
The US move draws on a longer international history. Screening programmes for DMD were initiated in Wales, France, Belgium, Cyprus, and Manitoba at various points, establishing proof of concept for the CK-based approach. Those programmes pre-dated the current therapeutic landscape. The ethical case for screening has fundamentally changed.
In Australia, the 2024 Lancet stakeholder study found broad support for newborn bloodspot screening, noting persistent failures to deliver equitable diagnoses, particularly for children from ethnic minority backgrounds. A workshop led by the Sydney Children’s Hospital Network has established protocols for a pilot programme in New South Wales and the Australian Capital Territory.
Within Europe, the EURO-NMD registry is working toward uniform data capture across all network members. Whether national governments will move toward formal newborn screening in the near term remains an open policy question, one that the EMA’s position on available therapies may complicate.
For limb-girdle muscular dystrophies, expert consensus published in Neurology in October 2025 underlined that precise and timely genetic diagnosis is crucial to enable access to clinical trials and natural history studies.
Support Infrastructure: Necessary but Not Sufficient
Muscular Dystrophy UK’s 2025 to 2035 strategy targets no one waiting longer than six months for a diagnosis by the end of the decade, committing to clinician education, a new referral service, and investment in novel diagnostic tools. The human cost is illustrated in its own documentation: a mother named Bethany waited nearly a year before her son Teddy received his DMD diagnosis, delivered by telephone with no offer of support.
The NeuroMuscular Centre in Cheshire, the Muscular Dystrophy Support Centre across the Midlands, Muscular Dystrophy Canada, CureDMD, and Muscular Dystrophy Australia all provide vital patient support and care navigation. But these organisations operate downstream of the diagnostic failure they are trying to compensate for.
The Access Gap Is the Defining Challenge
The convergence of new science, an expanding global pipeline, growing newborn screening momentum, and infrastructure such as EURO-NMD creates a genuine moment of opportunity. But it is accessible only to those who receive a diagnosis early enough to benefit.
The finding that DMD may originate in foetal development could shift the therapeutic window earlier than previously imagined. Mutation-agnostic approaches could expand eligibility beyond exon-specific therapies. Gene therapies, once their benefit-risk profile is more firmly established, may offer disease modification at scale.
None of this matters for a child who reaches school age without a diagnosis.
The gap between what the science makes possible and what systems currently deliver is not a research problem. Accelerating muscular dystrophy diagnosis is not a secondary concern, it is the prerequisite for every other advance to have meaning. It is a primary care education problem, a referral pathway problem, a genetic testing access problem, and a policy co-ordination problem that plays out differently, but persistently, in Berlin, Brisbane, Baltimore, and beyond.
The science is ready. The question is whether the systems can catch up before another generation of patients runs out of time.
